RaySearch postpones the publication of the company's interim report for January – June 2022

Report this content

RaySearch has decided to postpone the publication of the company's interim report for January 1 - June 30, 2022 to August 29, 2022. The previously stated date was August 25, 2022.
 
The reason for the postponement is that the company needs more time to clarify an accounting issue.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

Björn Hårdemark, interim CFO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0) 709 564 217
bjorn.hardemark@raysearchlabs.com

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.  

RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets.

Tags: